LYKALABS
Lyka Labs Limited (LYKALABS) Stock Analysis
Lyka Labs Limited is an Indian pharmaceutical company manufacturing formulations and APIs with a focus on niche therapies and contract manufacturing. It supplies domestic and export markets from regulated plants. The business competes in India's generic pharmaceutical industry. It is listed on Indian stock exchanges.
Healthcare › Biotechnology
₹87.80
+20.84% 1W | -15.60% 52W
Market Cap
317 CR
P/E Ratio
–
52W High
₹98.9
52W Low
₹44.1
Div. Yield
0%
Beta
0.6
50 DMA
₹76.3
200 DMA
₹67.4
Profit Margin
-6.6%
Inst. Own.
0%
⚠️ BREAKDOWN
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 | 42.31 |
| Expenses | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 | 39.20 | 29.08 | 34.48 | 37.76 |
| Operating Profit | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 | 1.65 | -6.45 | 4.55 |
| OPM % | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% | 5.37% | -23.01% | 10.75% |
| Other Income | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 | 0.42 |
| Interest | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.70 | 1.01 |
| Depreciation | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 |
| Profit before tax | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 | -0.16 | -8.58 | 1.95 |
| Tax % | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% | -5.13% |
| Net Profit | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 1.91 | 2.70 | 2.03 | 0.99 | -3.22 | -0.15 | -8.07 | 2.05 |
| EPS in Rs | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 | 0.00 | -2.13 | 0.57 |
| Metric | Jun 2015 | Mar 20169m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 | 138 |
| Expenses | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 132 | 141 |
| Operating Profit | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -3 | -3 |
| OPM % | 17% | 16% | 21% | -6% | -2.7% | -6% | 23% | 52% | 18% | 14% | 13% | -2.7% | -2.0% |
| Other Income | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 4 | 3 |
| Interest | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 | 3 |
| Depreciation | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 | 8 |
| Profit before tax | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | -12 | -11 |
| Tax % | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | -11% | |
| Net Profit | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | -10 | -9 |
| EPS in Rs | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | -2.81 | -2.50 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 11.0% | 8.0% | 0.0% |
| Profit CAGR | -32.0% | 1.0% | – |
Shareholding Pattern
Promoters58.16%
FIIs0.16%
DIIs0.66%
Public41.02%
Promoters58.16%
FIIs0.17%
DIIs0.66%
Public40.99%
Promoters58.16%
FIIs0.17%
DIIs0.66%
Public40.99%
Promoters58.16%
FIIs0.29%
DIIs0.66%
Public40.89%
Promoters58.45%
FIIs0.17%
DIIs0.66%
Public40.73%
Promoters51.00%
FIIs0.18%
DIIs3.74%
Public45.08%
Promoters54.81%
FIIs0.17%
DIIs0.81%
Public44.21%
Promoters58.16%
FIIs0.24%
DIIs0.66%
Public40.93%
Promoters58.16%
FIIs0.29%
DIIs0.66%
Public40.89%
Promoters58.45%
FIIs0.17%
DIIs0.66%
Public40.73%
LYKALABS
Holdings Analysis
Key strengths & risk signals
57
Overall
37
Fundamental
78
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
WEAK YEAR! Stock declined 15.6% in the last year.
Strengths (3)
BULLISH TREND! 50-day average (76.3) is above 200-day average (67.4) - positive signal.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 36,513 vs down days: 17,014. Ratio: 2.15x
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
57Overall
37Fundamental
78Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 13.3% (GOOD, 11/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -6.6% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 44.84% public ownership - higher volatility risk.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (76.3) is above 200-day average (67.4) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (87.8) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
2/10
WEAK YEAR! Stock declined 15.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 36,513 vs down days: 17,014. Ratio: 2.15x
RSI
3/5
BULLISH! RSI at 66.6 - positive momentum.
52W Range
4/5
UPPER HALF! Trading at 79.7% of 52W range - positive territory.
Momentum
4/5
GOOD MOMENTUM! Price has grown across all timeframes - up 20.8% (1 week), 9.6% (1 month), 25.2% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYKALABS | ₹87.80 | – | -6.6% | 13.3% | – | -15.6% | 57 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| HALEOSLABS | ₹1,532.40 | 29.3 | 4.9% | 0.3% | 14.7% | +37.4% | 64 | APPROACHING RESISTANCE | -38.1% | +550.0% | -11.6% | -2.9% |
| 3BBLACKBIO | ₹1,446.40 | 22.1 | 36.3% | 31.9% | 32.2% | +26.8% | 73 | APPROACHING RESISTANCE | -24.6% | -1.0% | +50.9% | -5.4% |
| PANACEABIO | ₹359.70 | – | -1.1% | 10.1% | – | -20.0% | 48 | CONSOLIDATING DOWN | -42.5% | +360.0% | +19.7% | +19.7% |
| DCAL | ₹149.80 | 146.9 | 0.6% | 9.0% | 21.0% | -45.7% | 50 | CONSOLIDATING DOWN | -347.9% | -367.3% | -4.2% | -20.4% |
| ZOTA | ₹1,409.30 | – | -17.0% | 56.7% | – | -11.1% | 56 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| SUPRIYA | ₹886.00 | 35.9 | 22.7% | 21.2% | 32.5% | +18.4% | 86 | CONSOLIDATING UP | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹520.60 | 38.4 | 26.5% | 9.4% | 15.7% | -22.2% | 70 | BREAKDOWN | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
